Core Insights - Carlsmed, Inc. has been added to the Russell 2000 Index, effective after market close on September 22, 2025, marking a significant milestone following its IPO in July 2025 [1][2] - The inclusion in the Russell 2000 Index is seen as validation of Carlsmed's differentiated business model and growth potential, enhancing its visibility among investors [2] Company Overview - Carlsmed is a medical technology company focused on AI-enabled personalized spine surgery solutions, aiming to improve healthcare outcomes and reduce costs associated with spine surgery [3] Industry Context - The Russell 2000 Index represents approximately 10 percent of the total market capitalization of the broader Russell 3000 Index, which is widely utilized by investment managers and institutional investors for benchmarking [2] - Approximately $9 trillion in assets are benchmarked against Russell's U.S. indexes, indicating the significance of the Russell 2000 Index in the investment landscape [2]

Core Insights - Carlsmed, Inc. has successfully completed its first cervical procedure using the aprevo system, marking a significant milestone in personalized spine surgery solutions [1][3] - The aprevo devices utilize an AI-powered surgical planning platform to customize surgical solutions based on individual patient anatomy and alignment needs [2][3] - The company aims to reduce revision surgeries and improve healthcare outcomes, with plans for a US commercial launch of the aprevo cervical device in 2026 after receiving FDA Breakthrough Device designation [3][4] Company Overview - Carlsmed is a medical technology company focused on AI-enabled personalized spine surgery solutions, with a mission to enhance surgical outcomes and reduce healthcare costs [4]